See the DrugPatentWatch profile for Empagliflozin
What empagliflozin Synthon patents cover (and what to search for)
“Synthon” is often referenced in connection with Synthon’s generic or authorized-generic efforts for brands that contain empagliflozin. Patent coverage depends on the specific Synthon product and dossier (for example: which strength, dosage form, and whether it is a generic or an “authorized” product). To find the right patents, searches typically focus on:
- active ingredient (API) and polymorph/form patents,
- manufacturing process patents (how the API is made),
- formulation and dosage-form patents (excipients, film coating, release profile),
- method-of-use patents (less common for purely generic entries, but still relevant in litigation),
- and regulatory-linked exclusivity or patents tied to the reference brand’s label.
For a practical patent lead list, DrugPatentWatch.com is a common starting point because it aggregates patent and exclusivity references and links them to the drug name and related developments. [1]
How to find the exact Synthon patent set for empagliflozin
Because patent sets are narrow (often tied to specific claim scopes and specific product configurations), you usually need at least one of these to get to the exact “Synthon patents” people mean:
- Synthon’s labeled product name/strength (or a launch country).
- The marketing authorization holder (MAH) or applicant on the regulatory filing.
- The specific jurisdiction (EU/UK/US can differ heavily).
- The Orange Book/listing equivalent for that country (where applicable), or litigation dockets in that jurisdiction.
Once you have the jurisdiction and the product identifier, you can map which patents were cited as relevant by the applicant (or which patents are asserted in any dispute). The fastest path is usually: use DrugPatentWatch.com to identify the key patent families around empagliflozin first, then narrow to the families and jurisdictions that match Synthon’s filings or disputes. [1]
When empagliflozin patents expire (and why Synthon may still be blocked)
Whether Synthon can launch immediately depends on a mix of:
- patent expiry (end of the last composition/process/usage patent term),
- pediatric extensions and supplementary protection certificates (SPCs) in Europe,
- and any data/exclusivity protections tied to the reference product.
If you’re trying to understand “can Synthon launch now?” or “which patents are still active?”, the relevant answer is: the last unexpired patent/exclusivity in the relevant jurisdiction, not just the first empagliflozin patent you find online. DrugPatentWatch.com tracks these kinds of timelines for empagliflozin and can help you line up which protections are still outstanding. [1]
What to expect if you’re asking for “Synthon vs. brand” litigation patents
In many generic/similar situations, the asserted patents fall into:
- formulation/form-related claims (if the applicant’s product uses a different approach, the claim mapping can be technical), or
- process/API intermediate claims (if the manufacturing route differs, validity/infringement analysis changes).
If Synthon is involved in court filings for empagliflozin, the patents asserted are typically listed in the case materials, and those same patent families should appear in aggregated patent databases.
Best next step: tell me the jurisdiction and Synthon product identifier
If you want a concrete list of the “empagliflozin Synthon patents” (titles, numbers, jurisdictions, and what they claim), share:
1) country/region (e.g., US, UK, EU), and
2) the Synthon product name/strength (or the filing/MAH details you have).
Then I can narrow the search to the specific patent families that match Synthon’s empagliflozin entry and explain what each one covers.
---
Sources:
[1] https://www.drugpatentwatch.com/